GlassScriptPhysician profile
Samuel Brandon New
NPI 1275823312
$1,531.86
in general payments reported to CMS, 2019-2025
28 companies · $152 in 2025
The $152 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $408 · 2020: $268 · 2021: $148 · 2022: $260 · 2023: $201 · 2024: $95.52 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $449.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $448.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $207.58 | 2020-2025 | |
| Pfizer INC. | $142.62 | 2019-2023 | |
| Coloplast Corp | $127.86 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $119.56 | 2021-2025 | |
| Medical Device Business Services, INC. | $118.94 | 2020 | |
| Therapeuticsmd, INC. | $85.72 | 2019-2022 | |
| Abbvie INC. | $80.80 | 2019-2023 | |
| Organon LLC | $79.83 | 2022-2025 | Nexplanon, Jada System |
| Merck Sharp & Dohme LLC | $68.76 | 2019-2023 | Gardasil 9 |
| Shield Therapeutics INC | $48.29 | 2022-2023 | Accrufer |
| Daiichi Sankyo INC. | $47.50 | 2019 | |
| Hologic Sales and Service, LLC | $45.38 | 2019-2021 | |
| Coopersurgical, INC. | $42.42 | 2022-2024 | Paragard T 380a |
| Sumitomo Pharma America, INC. | $33.43 | 2024-2025 | Myfembree |
| Exeltis, USA INC. | $31.25 | 2021-2025 | Slynd |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $30.37 | 2022 | |
| Allergan, INC. | $29.02 | 2019 | |
| Avion Pharmaceuticals | $28.99 | 2019-2020 | |
| Meditrina | $27.22 | 2019-2025 | |
| Astellas Pharma US INC | $21.99 | 2020 | |
| Ethicon US, LLC | $21.38 | 2019 | |
| Myovant Sciences INC. | $15.86 | 2022 | |
| Evofem Biosciences, INC. | $15.03 | 2022 | |
| Ferring Pharmaceuticals INC. | $13.73 | 2019 | |
| Scynexis, INC. | $12.68 | 2022 | |
| Agile Therapeutics, INC. | $12.19 | 2021 | |
| Amag Pharmaceuticals, INC. | $11.80 | 2019 | |
| Lupin INC. | $11.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel New listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.